Organon Completes JADA System Divestiture to Laborie Medical for Up to $465 Million

Organon has completed the divestiture of its JADA System to Laborie Medical Technologies Corp. for up to $465 million. The deal includes $440 million at closing and a potential earn-out of $25 million tied to 2026 revenue targets. The JADA System is used to treat postpartum hemorrhage and has helped over 136,000 women in 20 countries. The divestiture will strengthen Organon's balance sheet and support its capital allocation strategy for growth opportunities in women's health biopharmaceuticals.